viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus, and will pursue opportunities to address other serious virus-associated disease.
Company profile
Ticker
VIRX
Exchange
Website
CEO
Dayton Misfeldt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SUNESIS PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Viracta Royalty Fund, LLC ...
IRS number
943295878
VIRX stock data
Latest filings (excl ownership)
8-K
Other Events
9 Apr 24
8-K
Departure of Directors or Certain Officers
20 Mar 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
4 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
Transcripts
VIRX
Earnings call transcript
2020 Q3
16 Nov 20
VIRX
Earnings call transcript
2020 Q2
11 Aug 20
VIRX
Earnings call transcript
2020 Q1
10 May 20
VIRX
Earnings call transcript
2019 Q4
10 Mar 20
VIRX
Earnings call transcript
2019 Q3
12 Nov 19
VIRX
Earnings call transcript
2019 Q2
7 Aug 19
VIRX
Earnings call transcript
2018 Q1
8 May 19
VIRX
Earnings call transcript
2018 Q4
7 Mar 19
VIRX
Earnings call transcript
2018 Q3
5 Nov 18
VIRX
Earnings call transcript
2018 Q2
7 Aug 18
Latest ownership filings
3
Melody Burcar
22 Mar 24
4
Mark Rothera
13 Mar 24
4
Darrel P. Cohen
13 Mar 24
4
Daniel R. Chevallard
13 Mar 24
144
Notice of proposed sale of securities
27 Feb 24
4
IVOR ROYSTON
27 Feb 24
4
Roger Pomerantz
27 Feb 24
4
Daniel R. Chevallard
27 Feb 24
SC 13G
FORWARD VENTURES V LP
13 Feb 24
4
Mark Rothera
4 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.86 mm | 12.86 mm | 12.86 mm | 12.86 mm | 12.86 mm | 12.86 mm |
Cash burn (monthly) | 479.00 k | 884.67 k | 4.16 mm | 4.06 mm | 3.51 mm | 3.15 mm |
Cash used (since last report) | 3.18 mm | 5.88 mm | 27.62 mm | 26.96 mm | 23.33 mm | 20.91 mm |
Cash remaining | 9.67 mm | 6.98 mm | -14.77 mm | -14.10 mm | -10.47 mm | -8.05 mm |
Runway (months of cash) | 20.2 | 7.9 | -3.6 | -3.5 | -3.0 | -2.6 |
Institutional ownership, Q3 2023
67.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 46 |
Opened positions | 8 |
Closed positions | 7 |
Increased positions | 8 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 9.44 bn |
Total shares | 26.59 mm |
Total puts | 400.00 |
Total calls | 1.40 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Yair Chaim Schindel | 7.39 mm | $20.92 mm |
Biotechnology Value Fund L P | 3.83 mm | $0.00 |
BVF | 3.61 mm | $3.76 bn |
LVP Life Science Ventures Iii | 3.12 mm | $0.00 |
Forward Ventures V | 2.66 mm | $9.73 mm |
Citadel Advisors | 1.52 mm | $1.58 bn |
Vanguard | 1.15 mm | $1.19 bn |
Laurion Capital Management | 698.00 k | $725.92 mm |
Samsara BioCapital | 689.71 k | $717.30 mm |
BLK Blackrock | 306.49 k | $318.75 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Darrel P. Cohen | Stock Option Common Stock | Grant | Acquire A | No | No | 0.985 | 120,000 | 118.20 k | 120,000 |
12 Mar 24 | Daniel R. Chevallard | Stock Option Common Stock | Grant | Acquire A | No | No | 0.985 | 200,000 | 197.00 k | 200,000 |
12 Mar 24 | Mark Rothera | Stock Option Common Stock | Grant | Acquire A | No | No | 0.985 | 475,000 | 467.88 k | 475,000 |
27 Feb 24 | Daniel R. Chevallard | Common Stock | Sell | Dispose S | No | No | 0.7322 | 3,405 | 2.49 k | 102,306 |
25 Feb 24 | Daniel R. Chevallard | Common Stock | Option exercise | Acquire M | No | No | 0 | 6,889 | 0.00 | 105,711 |
25 Feb 24 | Daniel R. Chevallard | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 6,889 | 0.00 | 34,444 |
News
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
17 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
17 Apr 24
Oppenheimer Maintains Outperform on Viracta Therapeutics, Maintains $13 Price Target
17 Apr 24
HC Wainwright & Co. Reiterates Buy on Viracta Therapeutics, Maintains $4 Price Target
16 Apr 24
Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?
15 Apr 24
Press releases
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
21 Mar 24
Thinking about buying stock in Quantum-Si, Victoria's Secret, Viracta Therapeutics, CERo Therapeutics, or Weyerhaeuser?
8 Mar 24
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24